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Abstract
The effect of oral zinc (Zn) treatment was studied in the liver, kidneys and intestine of Long–Evans Cinnamon (LEC) rats in relation
to metals interaction and concentration of metallothionein (MT) and glutathione (GSH). We also investigated the change in the activity of
antioxidant enzymes and determined the biochemical profile in the blood and metal levels in urine. We showed that the Zn-treated group
had higher levels of MT in the hepatic and intestinal cells compared to both untreated and basal groups. Tissue Zn concentrations were
significantly higher in the Zn-treated group compared to those untreated and basal, whereas Cu and Fe concentrations decreased. The
antioxidant enzyme activities in the Zn-treated group did not change significantly with respect to those in the basal group, except for
hepatic glutathione peroxidase activity. Moreover, the biochemical data in the blood of Zn-treated group clearly ascertain no liver damage.
These observations suggest an important role for Zn in relation not only to its ability to compete with other metals at the level of
absorption in the gastrointestinal tract producing a decrease in the hepatic and renal Cu and Fe deposits, but also to MT induction as free
radical scavenger.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The Long–Evans Cinnamon (LEC) is an inbred strain
of Long–Evans rat which spontaneously develops acute
hepatitis at around 3–4 months after birth and then there is
a sudden onset of spontaneous hepatitis in LEC rats. Both
sexes are affected, but females are more vulnerable to
fulminant hepatitis. Kasai et al. [1] reported that 60–70%
of the males survive fulminant hepatitis, whereas only 20%
of the females do. These animals have a mutation in the
gene homologous to the human Wilson’s disease (WD)
gene, ATP7B [2]. A defect in the final product (Cu-binding
P-ATPase) of the gene, ATP7B, may cause a defect of Cu
excretion from hepatocyte into bile, resulting in hepatic Cu
accumulation [3]. Besides elevated hepatic Cu accumula-
tion similar to that occurring in WD, LEC rats also show
abnormal hepatic iron (Fe) overload depending on age [4].
Fe and Cu can induce free radical production, DNA
damage, protein or peptide modification, oxidation of
low-density lipoproteins and catalyze peroxidation of
membrane lipids [5,6]. Yamamoto et al. [7] observed that
increased levels of redox active free Cu in the liver of LEC
rats catalyze Fenton-type reactions, thus producing
hydroxyl radicals and lipid peroxidation (LPO) and caus-
ing the reduction of selenium-dependent glutathione per-
oxidase (Se-GPX) activity and the inactivation of catalase
(CAT). Significantly decreased Se-GPX, CAT and reduced
glutathione (GSH) and increased superoxide dismutase
(SOD) activity in the liver of acute Cu-poisoned rats have
also been reported [8]. On the other hand, Freedman et al.
[9], using a wild-type hepatoma cell line (HAC) selected
for Cu resistance, reported that over 60% of the cytosolic
Cu accumulated by these cells was bound to GSH and that
resistance was well correlated with elevated levels of the
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tripeptide. Some studies have reported on the ability of
zinc (Zn) to interact with Cu and Fe decreasing metal
content in tissues and retarding oxidative processes
[10,11]. Antagonism of redox-active transition metals, such
as Cu and Fe, and site-specific reactions has led to the
theory that Zn may be capable of reducing cellular injury
that might have a component of site-specific oxidative
damage [12].
The effectiveness of Zn in controlling Cu-inducing liver
damage has been documented in WD patients [13]. The
action mechanisms of Zn are not fully elucidated but
metallothionein (MT) induction in the gastrointestinal
mucosal cells seems to be responsible for trapping Cu in
the enterocytes. Thus, Zn acts by forming a mucosal block
for Cu absorption and increases the fecal excretion of Cu
[14]. Moreover, Zn-induced MT has been proposed to play a
role in the cellular protection against damage caused by
excessive Cu accumulated in tissues [15].
To verify the effectiveness of Zn therapy, we compared
the untreated with the Zn-treated LEC rat group (95 days
old) determining the effect of 60 days treatment on MT,
GSH, and trace element (Zn, Cu and Fe) content in the liver,
kidneys and intestine. We also studied the changes in the
activity of hepatic and renal free radical-metabolizing
enzymes, Cu,Zn-SOD, Se-GPX, total glutathione peroxi-
dase (T-GPX) and CAT and determined the biochemical
profile and metal levels in blood and urine, respectively. As
for the initial conditions, we measured the same parameters
in the basal group (35 days old).
2. Materials and methods
2.1. Animals
Thirty male LEC rats (35 days old, 90 g body weight)
from Charles River Japan (Tokyo, Japan) were used for the
study. They were kept on a standard laboratory diet (Morini
MIL GLP diets) containing 11.7 mg Cu/Kg and 67.5 mg Zn/
Kg and deionized water. They were housed in comfortable
cages at 20 jC with a 12-h light–dark cycle. Zn acetate
supplement was dissolved in 2% glucose solution in dis-
tilled water.
We divided the 30 rats as follows: 13 rats received by
gavage an oral dose of Zn acetate 50 mg/ml daily for 60
days (Zn-treated group); 13 rats received daily by gavage an
oral dose of glucose solution 0.02 mg/ml daily for 60 days
(untreated group); 4 rats received no treatment and they
were sacrificed 35 days after birth (basal group).
Rats were sacrificed under diethyl ether, liver, kidneys
and intestine were quickly removed, washed in saline
solution repeatedly, frozen with liquid nitrogen and stored
at  80 jC until used.
All procedures were carried out on laboratory rats
according to the regulations of the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
2.2. Determination of trace elements, MT and GSH contents
in hepatic, renal and intestinal tissues
A part of the tissues was homogenized in 4 vol of 20 mM
Tris–HCl buffer, pH 8.6, supplemented with 0.006 mM
leupeptine, 0.5 mM phenylmethylsulphonylfluoride (PMSF)
as antiproteolitic agents, and 0.01% h-mercaptoethanol as
reducing agent. The homogenate was centrifuged at 4 jC at
50400 g for 50 min, and the resulting supernatant was
used for Cu, Fe and Zn estimation by atomic absorption
spectrophotometry (Perkin-Elmer mod. 4000) and MT
quantification using the silver saturation method [16]. The
trace elements and MT amount in the supernatant was
expressed relative to total soluble cell protein assayed by
the Lowry method [17]. The metals were also determined in
the homogenate and expressed relative to dry weight.
For the GSH assays, tissue samples were homogenized in
5 vol of 5% 5-sulfosalicylic acid. To obtain supernatant
solutions, the homogenates were centrifuged at 16100 g
for 15 min at 4 jC. GSH was determined according to the
method of Anderson [18]. Values are reported in nanomoles
GSH per gram fresh weight.
2.3. Determination of trace elements in urine
To eliminate organic matter, 1 ml aliquots of urine
sample were digested in Teflon vessels with 0.5 ml nitric
acid AristaR in a microwave CEM mod. MDS-2000. Cu, Fe
and Zn were determined utilizing synthetic urine [19], used
as standard solution, and assayed by atomic absorption
spectrophotometry (Perkin-Elmer mod. 4000).
2.4. Determination of antioxidant enzymes activities
For the enzyme assays, tissue samples were homogen-
ized in 4 vol of Tris–HCl 10 mM (pH 7.6), DTT 1 mM,
KCl 0.15 M, sucrose 0.5 M. The homogenates were cen-
trifuged at 52000 g for 50 min at 4 jC. Spectrophoto-
metric measurements were carried out on a Perkin-Elmer
Lambda 10 spectrophotometer. Assays were performed
in duplicate or triplicate and assay temperatures were
20 jC.
The assay for the SOD activity utilizes the reduction of
nitro blue tetrazolium (NBT) as detector of O2
 and defines
SOD activity in terms of its ability to inhibit the reduction of
NBT due to O2
. A unit was defined as the amount needed to
cause half-maximal inhibition that can be achieved by SOD
[20]. CAT was determined according to the method of Aebi
[21] after the decomposition of H2O2 at 240 nm. One unit is
defined as the amount of enzyme that catalyzed the dis-
mutation of 1 Am of H2O2 per minute.
The measurement of the Se-GPX and T-GPX activities in
supernatant was determined by the method of Livingstone et
al. [22] using H2O2 or cumene hydroperoxide (CHP) as
substrate, respectively. One unit of GPX equals 1 Amol
glutathione oxidised per minute.
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All these values were referred to total proteins deter-
mined by the folin–phenol reagent [17].
2.5. Analyses of biochemical profiles in serum
Activities of aspartate amino transferase (AST) and
alanine amino transferase (ALT) were determined at 340
nm in units per liter of serum using an automatic analyzer
(Hitachi mod. 747), whereas total bilirubin (T-Bil) concen-
trations were measured at 570 nm in micromoles per liter of
serum. All procedures were carried out using a clinical
guide to laboratory tests [23,24].
2.6. Statistical analysis
All measurements were made in duplicate and results are
reported as meansF S.D. Statistical analysis was performed
with the Primer statistical program. Statistical differences
were calculated with one-way analysis of variance
(ANOVA) with a Student–Newman–Keuls follow-up test.
Significant difference was accepted at P < 0.05.
3. Results
3.1. Concentrations of trace elements in the organs and
urine
The trace element concentrations in hepatic, renal and
intestinal supernatant and urine of Zn-treated, untreated and
basal groups are shown in Tables 1 and 2.
Zn concentrations were significantly higher in the Zn-
treated group than in both untreated and basal groups in all
organs considered. In particular, we observed that, in the
hepatic, renal and intestinal supernatant fraction, Zn levels
were 1.25-, 2- and 2-fold, respectively, higher than both the
untreated and basal groups. Instead, Cu and Fe levels were
significantly lower in the Zn-treated group than in the
untreated one in liver, kidneys and intestine. In fact, we
found high levels of Cu and Fe concentrations in the liver of
the untreated group (2.5F 0.6 and 2.1F1.0 Ag/mg, respec-
tively), as expected. It is well known that hepatic Cu and Fe
concentrations increase notably with age in LEC rats and are
an important factor contributing to liver injury in these rats
[4,25]. Moreover in the organs, Cu concentration in the Zn-
treated group was similar to those in the basal one, whereas
Fe levels were lower in the liver and higher in the kidneys.
In urine, Zn concentrations were significantly higher in
the Zn-treated group than in both the untreated and basal
groups, whereas Cu and Fe decreased significantly com-
pared to untreated one.
3.2. Quantification of MT and GSH in the organs
As shown in Table 1, the hepatic and intestinal MT
concentrations in the Zn-treated group were 1.3-fold
higher than in the untreated group concentrations and 3-
and 3.3-fold, respectively, than the basal one. The renal
MT concentrations in the Zn-treated group were also 3.3-
fold higher than in the basal group, whereas there were no
significant differences compared to those in the untreated
group. On the other hand, the hepatic and renal GSH
concentrations in the Zn-treated group were significantly
lower (0.55- and 0.67-fold, respectively) than in the
untreated one. In the kidneys, GSH concentrations in the
Table 1
Cu, Zn, Fe, MT and GSH levels in liver, kidneys and intestine of basal LEC
rats (Basal group), untreated LEC rats (Untreated group) for 60 days and
treated LEC rats (Treated group) with ZnAc for 60 days
Cu Zn Fe MT GSH
Liver
Basal
group
(Bg)
1.3F 0.2 0.4F 0.0 0.8F 0.2 4.2F 0.9 3810.5F 568.6
Untreated
group
(Ug)
2.5F 0.6 0.4F 0.2 2.1F1.0 9.6F 2.2 5987.2F 1771.8
Treated
group
(Tg)
1.6F 0.3 0.5F 0.1 0.4F 0.1 12.3F 3.3 3309.6F 1002.6
P-value
Bg vs. Ug * – * * *
Bg vs. Tg – * * * –
Tg vs. Ug * * * * *
Kidneys
Basal
group
(Bg)
0.04F 0.0 0.2F 0.0 0.3F 0.1 1.7F 0.3 2970.7F 10.8
Untreated
group
(Ug)
1.8F 0.5 0.2F 0.0 0.5F 0.1 6.5F 1.5 7860.6F 14.8
Treated
group
(Tg)
0.07F 0.0 0.4F 0.1 0.4F 0.0 5.6F 0.7 5310.2F 27.6
P-value
Bg vs. Ug * – * * *
Bg vs. Tg – * * * *
Tg vs. Ug * * * – *
Intestine
Basal
group
(Bg)
0.05F 0.0 0.2F 0.0 0.1F 0.0 2.7F 0.8 1550.0F 286.5
Untreated
group
(Ug)
0.05F 0.0 0.2F 0.0 0.2F 0.0 7.1F 2.0 1124.6F 417.6
Treated
group
(Tg)
0.03F 0.0 0.4F 0.1 0.1F 0.0 8.9F 1.8 1114.7F 670.9
P-value
Bg vs. Ug – – – * –
Bg vs. Tg * * * * –
Tg vs. Ug * * * * –
Values are indicated as meanF S.D. in micrograms per milligram protein
for metals and MTs and nanomoles per milligram fresh weight for GSH.
Significantly different for Bg = Basal group; Ug = Untreated group;
Tg = Treated group.
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Zn-treated group were significantly higher (1.7-fold) than
in the basal group. Moreover, there were slight, but not
significant differences in the intestinal GSH concentrations
among the three groups. Furthermore, both hepatic and
renal MT and GSH concentrations in the untreated group
were significantly higher compared to those in the basal
one. In particular, hepatic and renal MT concentrations
were 2.3- and 3.8-fold, respectively, higher compared to
those in the basal group and GSH concentrations were
1.6- and 2.6-fold, respectively, than those in the basal
group.
3.3. Antioxidant enzymes and serum biochemical profile
Fig. 1 shows that Cu,Zn-SOD activity was similar in the
liver of the three groups, whereas renal enzyme activity
levels were significantly different between Zn-treated and
untreated groups. In particular, renal Cu,Zn-SOD activity
was significantly higher (1.4-fold) in the untreated group
compared to the Zn-treated group. On the other hand, CAT
activity in the liver of Zn-treated group was 3.1-fold higher
than in untreated one, whereas no significant difference was
noted between those Zn-treated and basal. Moreover, CAT
activity in the untreated group was significantly lower (0.3-
fold) compared to that in the basal group. In the kidneys,
CAT activity was at a similar level among the three groups.
In the liver, the levels of Se-GPX activity were significantly
lower (0.6-fold) in the Zn-treated group than in the basal
ones, whereas no significant difference was observed
between the same groups in the kidneys. Even, no signifi-
cant difference was observed between Zn-treated and
untreated groups in the liver, whereas in the kidneys, Se-
GPX activity in the untreated group was 1.7-fold higher
with respect to that in the Zn-treated group. With regard to
T-GPX activity, we observed in the liver, enzyme activity
levels were significantly higher (1.73- and 1.44-fold, respec-
tively) in the untreated group than both the Zn-treated and
basal groups, whereas no significant difference was
observed between Zn-treated and basal groups. In the
kidneys, T-GPX activity was significantly higher (2.9- and
2.7-fold, respectively) in the untreated group than both the
Zn-treated and basal groups.
Serum AST and ALT activities, and T-Bil concentrations
in the Zn-treated rats were almost the same as those in the
 
 
 
 
Fig. 1. Cu,Zn-SOD, CAT, Se-GPX and T-GPX activity in liver and kidney
cytosol from basal LEC rats (Basal group), untreated LEC rats (Untreated
group) for 60 days and treated LEC rats (Zn-treated group) for 60 days. The
results are expressed as meanF S.D. (n= 4 for the basal group; n= 13 for
the untreated group; n= 13 for the Zn-treated group). Different letters
correspond to significant statistical differences for P< 0.05.
Table 3
Serum AST and ALT activities, and T-Bil concentrations in basal LEC rats
(Basal group), untreated LEC rats (Untreated group) for 60 days and treated
LEC rats (Treated group) with ZnAc for 60 days
AST ALT T-Bil
Serum
Basal group (Bg) 181.3F 39.8 51.0F 12.8 1.1F 0.2
Untreated group (Ug) 523.8F 147.8 336.2F 138.4 621.5F 171.1
Treated group (Tg) 151.3F 81.3 71.4F 30.4 1.7F 0.7
P-value
Bg vs. Ug * * *
Bg vs. Tg – – –
Tg vs. Ug * * *
Values are indicated as meanF S.D. in units per liter for AST and ALT, and
in micromoles per liter for T-Bil. Significantly different for P < 0.05.
Bg =Basal group; Ug =Untreated group; Tg =Treated group.
Table 2
Cu, Zn and Fe in urine of basal LEC rats (Basal group), untreated LEC rats
(Untreated group) for 60 days and treated LEC rats (Treated group) with
ZnAc for 60 days
Cu Zn Fe
Urine
Basal group (Bg) 0.40F 0.1 0.7F 0.0 0.6F 0.1
Untreated group (Ug) 26.6F 3.8 4.1F1.2 1.9F 0.8
Treated group (Tg) 0.80F 0.2 6.5F 2.0 0.4F 0.1
P-value
Bg vs. Ug * * *
Bg vs. Tg * * –
Tg vs. Ug * * *
Values are indicated as meanF S.D. in micrograms per milliliter.
Significantly different for P < 0.05. Bg =Basal group; Ug =Untreated
group; Tg = Treated group.
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basal rats. Untreated rats showed a significant increase in
AST (523.8F 147.8) and ALT (336.2F 138.4) activities,
and T-Bil concentrations (621.5F 171.1), as summarized in
Table 3.
4. Discussion
In our report, we describe the effect of 60 days treatment
with Zn acetate on MT, GSH and metal content (Zn, Cu and
Fe), evaluate the changes in the activity of antioxidant
enzymes and determine the biochemical serum profile and
trace elements concentrations in urine of LEC rats, an
animal model of WD.
Several papers have discussed the relationship between
oxidative stress and hepatic accumulation of toxic metals in
LEC rats [26–28]. However, none of the papers investigated
the antioxidant effect and possible role of Zn supplementa-
tion in these rats. The role of Zn in protecting biological
structures from free radical damage may be due to several
factors: maintaining an adequate level of MTs, which are
also free radical scavengers; as an essential component of
Cu,Zn-SOD; as a protective agent for thiols and other
chemical groups [29].
Our results show that, in general, treatment with zinc
acetate increases tissue Zn and MT contents and decreases
Cu and Fe concentrations in the liver, kidney and intestine
supernatant fraction. The reduction of Cu and Fe is accom-
plished through competition mechanisms by decreasing the
intestinal absorption of Cu and Fe and by enhancing metal
excretion [30]. Cousins and McMahon [31] reported that the
Fe transporter Nramp 2 (divalent cation transporter -1) also
exhibits Zn transport capabilities. We suppose that in the
presence of large amounts of Zn, this transporter might bind
more Zn than Fe causing a decrease in Fe content in tissues.
It is well known that Zn is thought to be a more potent
inducer of MT than Cu; however, MT has much higher
affinity for Cu than Zn, resulting in Cu sequestration within
enterocytes [32]. The complexation of Cu prevents its
serosal transfer resulting in a decrease in serum Cu levels
and its excretion into the feces along with intestinal cells
[33]. In urine, Cu and Fe concentrations decreased signifi-
cantly compared to untreated one, whereas Cu concentra-
tions were significantly higher in the Zn-treated group than
in basal groups. We postulated that Zn, at high doses, might
interact with Cu for the ligand sites on MT, as suggested by
our previous reports [34], decreasing metal content in both
hepatic and renal cells. Moreover, Zn-induced MT protects
against accumulated Cu toxicity in the liver and kidneys,
suggesting that this protein might be important in the
cellular defence against oxidative stress.
Whereas MT induction plays a part in Zn protective
action, other factors, such as GSH, may also be involved
because protection is offered even in MT-null mice [35].
Our results show that the hepatic GSH concentrations were
at similar levels in both the Zn-treated and basal groups.
Maintenance of normal GSH status is essential for Zn
protection, as inhibition of GSH synthesis abolishes this
protection. This proposal is based on observations that GSH
depletion potentiates metal toxicity in rats, mice, and
cultured cells [36]. In our work, we observed that the
hepatic and renal GSH concentrations in the untreated
group, in which there was an abnormal Cu accumulation,
were 1.8- and 1.5-fold, respectively, higher than the Zn-
treated group and 1.6- and 2.6-fold, respectively, higher than
the basal groups. Jime`nez and Speisky [37], in an in vitro
study on the effects of Cu ions on the free radical-scaveng-
ing properties of GSH, showed that besides preventing the
occurrence of a redox-active Cu, a Cu–GSH complex could
per se also act to scavenge free-radical species. GSH se-
questers redox active Cu ions preventing them from cata-
lyzing free radical generation. The formation of Cu–GSH
complexes could be regarded as an additional mechanism in
the protection of cells against excessive Cu exposure.
GSH is also a substrate for GSH peroxidases (Se-GPX
and T-GPX), enzymes capable of both removing hydrogen
peroxide from the cells and repairing peroxidatively dam-
aged membranes. Downey et al. [38] showed that the LEC
rat possesses a deficiency in hepatic selenium (Se) and
reduced levels of both hepatic Se-GPX RNA, and Se-GPX
activity. Around 65% of dietary Se in the rat is thought to be
associated with the liver, and the cause of hepatic Se
deficiency in LEC rats is elusive. Our data demonstrate that
the levels of hepatic Se-GPX activity were significantly
lower in the Zn-treated group than in the basal one,
suggesting that this deficiency may be caused by the
increased Se excretion and/or decreased Se absorption. It
is also possible that Zn and Se can compete with each other
for binding to a number of proteins leading to a deficiency
in cellular Se. It is also true, that Se-GPX activity was
significantly lower in the untreated group than in the basal
one. Other studies are needed to clarify the role of Zn and
Cu in relation to the changes of Se-GPX activity in LEC
rats. We also observed that the levels of both Se-GPX and
CAT activity in the liver were significantly higher (1.3- and
3.6-fold, respectively) in basal group than in untreated
animals. Yamamoto et al. [7] reported that in the liver of
LEC rats with excess amounts of Cu, the increased LPO and
the ROSs generated from free Cu are thought to be involved
in the inactivation of CAT in much the same way as in
Indian childhood cirrhosis, a disease which shares similar
types with WD. Se-GPX deficiency in the LEC rat is likely
to exacerbate the anaemia that occurs concomitantly with
acute hepatitis [39]. On the other hand, T-GPX activity
levels were significantly higher in the untreated group than
both the Zn-treated and basal groups in the liver and
kidneys, whereas no significant difference was observed
between Zn-treated and basal groups. It is known that
hydrogen peroxide (H2O2) and consequently hydroxyl rad-
ical are generated during Cu-catalyzed GSH oxidation. The
cyclic regeneration of GSH from GSSG by NADPH-
dependent GSSG-R may cause sustained generation of
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hydroxyl radical in the presence of excess free Cu. An
increased activity of total T-GPX in the untreated group may
be explained as a protective cell mechanism against an
increased generation of H2O2 caused by both Cu and Fe
accumulation in tissues.
No significant change was noted in Cu,Zn-SOD activity
in the liver and kidneys among the three groups, except for
renal enzyme activity levels between Zn-treated and un-
treated groups. Similar findings were found by Ohhira et al.
[26] in the liver of LEC rats before and after the onset of
hepatitis. The significant increase of Cu,Zn-SOD activity
observed in the kidneys of the untreated group probably
indicates a response to the excessive production of super-
oxide anion (O2
).
Moreover, we observed an abnormal serum T-Bil con-
centration in the untreated group, whereas there were no
significant differences between Zn-treated and basal groups.
Serum T-Bil concentration showed a similar pattern to
serum ALT and AST. These findings accorded well with
those of Nomiyama et al. [40] who noted a significant
increase in these serum activities in the period between of
12–16 weeks and upon the onset of jaundice in LEC rats.
The maintenance on basal levels of the antioxidant
enzymes activities, of GSH content and other serum bio-
chemical parameters in Zn-treated group strongly support
the hypothesis of ability of Zn to retard oxidative mecha-
nisms, suggesting a role in modulating ROSs. Zn treatment
interrupts the pathological process that leads to induction of
the antioxidants in the diseased tissue. This effect of Zn is
based on the observation that during the course of the
experiment, over 50% of untreated rats get the jaundice
acute hepatitis and then die, whereas all Zn-treated rats
survived. We believe that this protective effect of Zn is
related not only to the ability of Zn to compete with other
metals at the level of absorption in the gastrointestinal tract
producing a decrease in the hepatic and renal Cu and Fe
deposits, but also to MT induction as free radical scavenger
or both hypotheses could be true. In this contest, LEC rats
seem to be a good animal model which elucidates the
pathological relationship among free radicals, metal toxicity,
and hepatorenal injury. We postulate that these findings are
useful in improving our knowledge on pathophysiology of
WD.
Further research is being carried out to evaluate the
antioxidant properties of Zn and Zn-MT in relation to
apoptotic processes as cellular response to DNA damage
by free radicals.
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